New bone-targeted agents for osteoporosis must clear significant obstacles to succeed in a highly generic market, but safety concerns with established agents like bisphosphonates and calcitonin offer a foothold. Phase III anabolic candidates from Amgen and Radius Health aim to build new bone, the holy grail of osteoporosis treatment, but R&D in new anti-resorptive mechanisms to halt bone breakdown also continues.

START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in the fields of in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.